{
    "clinical_study": {
        "@rank": "146292", 
        "arm_group": {
            "arm_group_label": "Prednisone", 
            "arm_group_type": "Other", 
            "description": "Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication."
        }, 
        "brief_summary": {
            "textblock": "Would systemic steroids be an effective treatment in early variants of achalasia?"
        }, 
        "brief_title": "Assessing the Efficacy of Steroid Treatment of Achalasia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Achalasia", 
        "condition_browse": {
            "mesh_term": "Esophageal Achalasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Adults ages 18-90 with a diagnosis of achalasia confirmed by findings on esophageal\n             manometry and barium esophagogram will be eligible for the study.\n\n          -  Eckardt score6 greater or equal to 6 or 2 or greater for dysphagia and/or\n             regurgitation\n\n          -  Symptoms less than 2 years\n\n        Exclusion criteria:\n\n          -  Medical conditions such as severe heart or lung disease that preclude safe\n             performance of endoscopy and injection;\n\n          -  Greater than mild esophageal dilation\n\n          -  Type 1 achalasia as defined by the Chicago classification scheme7 and/or esophageal\n             diameter > 3cm;\n\n          -  Prior treatment for achalasia\n\n          -  Use of medications that might affect LES pressure such as anticholinergics or calcium\n             channel antagonists\n\n          -  Symptom duration greater than 2 years\n\n          -  Inability to read due to: Blindness, cognitive dysfunction, or English language\n             illiteracy\n\n          -  Disorders which predispose to unreliable responses such as Schizophrenia, Alzheimer's\n             disease or significant memory loss\n\n          -  Pregnant and lactating females will be excluded as steroids are not thought safe for\n             the fetus."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903486", 
            "org_study_id": "12-009825"
        }, 
        "intervention": {
            "arm_group_label": "Prednisone", 
            "description": "Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.", 
            "intervention_name": "Apo-Prednisone Cordorol, Detasone - Prednisone", 
            "intervention_type": "Drug", 
            "other_name": [
                "Prednisone", 
                "Anti-inflamatory", 
                "Corticosteroid"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Trouble swallowing", 
            "dysphagia", 
            "disorder of the esophagus"
        ], 
        "lastchanged_date": "July 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Karthik Ravi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the proportion of patients with an Eckhart score  \u2265 6 at 1 month", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903486"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Karthik Ravi, M.D.", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "proportion of patients with symptomatic improvement (Eckardt sore 6 or greater)", 
            "safety_issue": "No", 
            "time_frame": "baseline to 1 year"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}